[go: up one dir, main page]

AR005658A1 - Una molecula de acido nucleico aislada que codifica la región determinante de complementariedad de inmunoglobulina. - Google Patents

Una molecula de acido nucleico aislada que codifica la región determinante de complementariedad de inmunoglobulina.

Info

Publication number
AR005658A1
AR005658A1 ARP970100204A ARP970100204A AR005658A1 AR 005658 A1 AR005658 A1 AR 005658A1 AR P970100204 A ARP970100204 A AR P970100204A AR P970100204 A ARP970100204 A AR P970100204A AR 005658 A1 AR005658 A1 AR 005658A1
Authority
AR
Argentina
Prior art keywords
nucleic acid
determining region
coding
isolated nucleic
monoclonal antibody
Prior art date
Application number
ARP970100204A
Other languages
English (en)
Original Assignee
Univ Vermont
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vermont, Smithkline Beecham Corp filed Critical Univ Vermont
Publication of AR005658A1 publication Critical patent/AR005658A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de un anticuerpo monoclonal anti-factor de coagulación para la preparación de un medicamento para inhibir trombosis en un animal, quecomprende una dosis eficaz de un anticuerpo monoclonal anti-factor de coagulación que tieneac tividad neutralizante autolimitante. Se describe ademásun anticuerpo monoclonal anti-factor de coagulación, un hibridoma, un fragmento fab neutralizante, una región determinante de complementariedad de la cadenapesada de inmunoglobulina, unamolécula de ácido nucleico, un anticuerpo alterado y humanizado y una composición farmacéutica.
ARP970100204A 1996-01-17 1997-01-17 Una molecula de acido nucleico aislada que codifica la región determinante de complementariedad de inmunoglobulina. AR005658A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1010896P 1996-01-17 1996-01-17
US2911996P 1996-10-24 1996-10-24

Publications (1)

Publication Number Publication Date
AR005658A1 true AR005658A1 (es) 1999-07-14

Family

ID=26680794

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970100204A AR005658A1 (es) 1996-01-17 1997-01-17 Una molecula de acido nucleico aislada que codifica la región determinante de complementariedad de inmunoglobulina.

Country Status (25)

Country Link
US (5) US6005091A (es)
EP (2) EP1007089B1 (es)
JP (2) JP2000503210A (es)
KR (1) KR100553629B1 (es)
CN (1) CN1213312A (es)
AR (1) AR005658A1 (es)
AT (1) ATE330630T1 (es)
AU (1) AU706397B2 (es)
BR (1) BR9707049A (es)
CZ (1) CZ299452B6 (es)
DE (1) DE69736197T2 (es)
DK (1) DK1007089T3 (es)
ES (1) ES2267131T3 (es)
HU (1) HU225903B1 (es)
ID (1) ID17156A (es)
IL (1) IL125380A0 (es)
MA (1) MA24512A1 (es)
MX (1) MX9805810A (es)
NO (1) NO983284L (es)
NZ (2) NZ501215A (es)
PL (1) PL187274B1 (es)
PT (1) PT1007089E (es)
SI (1) SI1007089T1 (es)
TR (1) TR199801390T2 (es)
WO (1) WO1997026010A1 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20040038898A1 (en) * 1996-05-16 2004-02-26 The Trustees Of Columbia University Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
WO1999001476A1 (en) * 1997-07-03 1999-01-14 Smithkline Beecham Corporation CRYSTAL STRUCTURES OF ANTI-FACTOR IX Fab FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN
DE19802139C1 (de) * 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
JP2002514422A (ja) * 1998-05-08 2002-05-21 ステイヒテイング・サンキン・ブロードボールジーニング インヒビターを有する血友病ａ患者の診断および治療方法
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
PT1107996E (pt) 1998-08-28 2002-10-31 Genentech Inc Anticorpos humanos anti-factor ix/ixa
WO2000026394A1 (en) * 1998-10-31 2000-05-11 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Variants of humanized anti-carcinoma monoclonal antibody cc49
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
EP1194528B1 (en) * 1999-07-14 2007-03-07 D. Collen Research Foundation vzw Monoclonal antibody for factor VIII, which even when present in molar excess inactivates factor VIII only in part and a method for producing such an antibody
US7067313B1 (en) 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
US7829085B2 (en) * 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US6316259B1 (en) * 2000-01-21 2001-11-13 Isis Pharmaceuticals, Inc. Antisense inhibition of glycogen synthase kinase 3 alpha expression
BR0015872A (pt) * 2000-05-15 2004-08-03 Smithkline Beecham Corp Agentes antitrombóticos
EP2325337A1 (en) * 2000-09-26 2011-05-25 Duke University RNA aptamers and methods for identifying the same
EP1222929B8 (en) 2001-01-11 2010-07-07 Life Sciences Research Partners VZW Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
AU2002252456A1 (en) * 2001-03-23 2002-10-08 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
JP4205576B2 (ja) * 2001-06-12 2009-01-07 財団法人化学及血清療法研究所 ヒト型抗血液凝固第ｖｉｉｉ因子抗体
US20030021786A1 (en) * 2001-07-09 2003-01-30 Gevas Philip C. Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
WO2003013423A2 (en) * 2001-08-05 2003-02-20 Gvg, Inc. Antithrombotic agent
US20040052779A1 (en) * 2001-12-21 2004-03-18 Stinson Jeffrey R. Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US7569673B2 (en) 2002-06-28 2009-08-04 The United States Of America As Represented By The Department Of Health And Human Services Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors
US6928528B1 (en) 2002-10-07 2005-08-09 Advanced Micro Devices, Inc. Guaranteed data synchronization
KR20050118690A (ko) * 2003-03-28 2005-12-19 애프톤 코포레이션 가스트린 호르몬 면역어세이
JP4422430B2 (ja) 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
AU2004264265C1 (en) 2003-08-14 2012-06-28 Thrombogenics Nv Antibodies against factor VIII with modified glycosylation in the variable region
WO2005021594A2 (en) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
WO2005035754A1 (ja) * 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
CA2561405C (en) * 2004-03-29 2014-01-21 Receptor Biologix, Inc. Monoclonal antibodies to gastrin hormone
DK1794586T3 (da) * 2004-09-22 2013-05-13 Cancer Advances Inc Monoklonale antistoffer til progastrin
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
US20100322921A1 (en) * 2006-10-16 2010-12-23 Rekha Bansal METHOD OF INHIBITING COAGULATION ACTIVATION WITH HUMAN ANTI-FACTOR Va ANTIBODIES AND USE THEREOF
WO2009033743A1 (en) * 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
WO2009033309A1 (en) 2007-09-13 2009-03-19 Esbatech Ag HUMANIZED ANTIBODIES AGAINST THE ß-AMYLOYD PEPTIDE
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
WO2009049234A2 (en) * 2007-10-11 2009-04-16 Regents Of The University Of California Methods of treating coagulopathy
TR201820051T4 (tr) * 2008-06-19 2019-01-21 Prothix Bv Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
EA031025B1 (ru) 2012-12-21 2018-11-30 Сиэтл Дженетикс, Инк. Антитела против ntb-a и связанные с ними композиции и способы
WO2014160088A2 (en) * 2013-03-14 2014-10-02 Rhode Island Hospital, A Lifespan-Partner Treating hepatitis b virus infections
AU2014325063B2 (en) 2013-09-27 2019-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
MA40512A (fr) 2014-08-07 2021-03-24 Novartis Ag Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US10913802B2 (en) * 2015-07-21 2021-02-09 Dyax Corp. Monoclonal antibody inhibitor of factor XIIA
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
BR112018009312A8 (pt) 2015-12-28 2019-02-26 Chugai Pharmaceutical Co Ltd método para promover eficiência de purificação de polipeptídeo contendo região de fc
MA43660A (fr) 2016-01-22 2018-11-28 Adimab Llc Anticorps anti-facteur xi de coagulation
SG11201807765PA (en) 2016-04-28 2018-10-30 Chugai Pharmaceutical Co Ltd Antibody-containing preparation
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
TWI752964B (zh) 2016-06-14 2022-01-21 美商默沙東藥廠 抗凝血因子ｘｉ抗體
EP3509637B1 (en) 2016-09-06 2024-11-27 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
MX2019005772A (es) * 2016-11-23 2019-10-02 Bioverativ Therapeutics Inc Anticuerpos mono y biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x.
IL308980A (en) 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods of their use
CN110325211A (zh) * 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
EP3624841A4 (en) 2017-06-15 2021-01-27 Cancer Advances, Inc., COMPOSITIONS AND METHODS FOR INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
CA3071236A1 (en) 2017-09-29 2019-04-04 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
CR20240273A (es) 2017-11-01 2024-08-27 Chugai Pharmaceutical Co Ltd Variantes e isoformas de anticuerpos con actividad biológica reducida (divisional 2020-229)
WO2020128049A1 (en) 2018-12-21 2020-06-25 Kymab Limited Fixaxfx bispecific antibody with common light chain
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3909799A1 (de) * 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
WO1993009804A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5383928A (en) * 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
EP0658168B1 (en) * 1992-08-27 2000-11-15 Stichting Sanquin Bloedvoorziening Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
US5397581A (en) * 1993-02-05 1995-03-14 Lerman; Russell E. Means for continuous confectionery coating of edible centers
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20070190059A1 (en) * 1996-01-17 2007-08-16 Smithkline Beecham Corporation Antithrombotic agents

Also Published As

Publication number Publication date
JP2000503210A (ja) 2000-03-21
HK1029513A1 (en) 2001-04-06
MA24512A1 (fr) 1998-12-31
US6391299B1 (en) 2002-05-21
PL327929A1 (en) 1999-01-04
CZ222598A3 (cs) 2000-01-12
US20020146411A1 (en) 2002-10-10
IL125380A0 (en) 1999-03-12
ID17156A (id) 1997-12-04
EP1007089A1 (en) 2000-06-14
DE69736197T2 (de) 2007-06-21
US20070224198A1 (en) 2007-09-27
BR9707049A (pt) 2000-10-24
WO1997026010A1 (en) 1997-07-24
AU706397B2 (en) 1999-06-17
NO983284L (no) 1998-09-16
SI1007089T1 (sl) 2006-12-31
HUP9900396A2 (hu) 1999-05-28
HUP9900396A3 (en) 2001-10-29
EP1007089A4 (en) 2003-04-16
US6005091A (en) 1999-12-21
DK1007089T3 (da) 2006-10-09
NZ501215A (en) 2001-04-27
JP2007325602A (ja) 2007-12-20
HU225903B1 (en) 2007-12-28
PL187274B1 (pl) 2004-06-30
AU1830897A (en) 1997-08-11
CN1213312A (zh) 1999-04-07
DE69736197D1 (de) 2006-08-03
KR100553629B1 (ko) 2006-10-04
KR19990077329A (ko) 1999-10-25
EP1007089B1 (en) 2006-06-21
CZ299452B6 (cs) 2008-07-30
TR199801390T2 (xx) 1998-12-21
MX9805810A (es) 1998-11-30
PT1007089E (pt) 2006-11-30
US20070003553A1 (en) 2007-01-04
NZ331014A (en) 2000-01-28
ES2267131T3 (es) 2007-03-01
NO983284D0 (no) 1998-07-16
EP1832297A1 (en) 2007-09-12
ATE330630T1 (de) 2006-07-15

Similar Documents

Publication Publication Date Title
AR005658A1 (es) Una molecula de acido nucleico aislada que codifica la región determinante de complementariedad de inmunoglobulina.
KR960704576A (ko) CD40에 대한 항체(Antibodies to CD40)
NO2006008I1 (no) Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
ATE531812T1 (de) Humanisierung von nager-antikörpern
HRP20020693B1 (hr) HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
CO5160384A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que comprende el mismo
UA41929C2 (uk) Анти-ефрр одноланцюжковий fv,молекула днк,яка його кодує, анти-ефрр антитіло,спосіб одержання анти-ефрр одноланцюжкового fv,спосіб одержання повного анти-ефрр антитіла та фармацевтична композиція (варіанти)
ATE208820T1 (de) Humanisierte antikoerper
BR9507594B1 (pt) anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteìna recombinante.
DE69940364D1 (de) Fab Fragmentbibliotheken und Verfahren für deren Verwendung
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
PT941121E (pt) Preparados farmaceuticos liofilizados, estaveis, de anticorpos monoclonais ou policlonais
ATE321788T1 (de) Humanisiertes immunglobulin gegen den alpha4beta7-integrin
ES2173130T3 (es) Metodo de fijacion de material al peptido beta-amiloide.
BR9607171A (pt) Anticorpos monoclonais anti-cd6 e usos dos mesmos
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
IT1271461B (it) Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
EE04752B1 (et) Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine
BR0207151A (pt) Moléculas de aglutinação terapêuticas
EA200400930A1 (ru) Блокирующее моноклональное антитело к vla-1 или его применение для лечения воспалительных заболеваний
MX9706588A (es) Metodo para estimular una respuesta inmune.
PT840620E (pt) Antagonistas de il-8 para o tratamento de asma
ATE296316T1 (de) Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung
CY1107785T1 (el) Χρηση του βασιλιξιμαμπ στη θεραπεια της ρευματοειδους αρθριτιδας ´η νοσων του δερματος

Legal Events

Date Code Title Description
FG Grant, registration